Compare Nuwellis Inc (NUWE) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs T Rowe Price Group Inc — how do they compare? Nuwellis Inc trades at $0.8 (market cap $2.50M), while T Rowe Price Group Inc trades at $107.71 (market cap $23.34B). The key difference: T Rowe Price Group Inc is far larger — about 9336× Nuwellis Inc's market cap, and T Rowe Price Group Inc pays a 4.75% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| NUWE | TROW | |
|---|---|---|
Market Cap | $2.50M | $23.34B |
Sector | Technology | Financials |
52-Week High | $164.50 | $121.68 |
52-Week Low | $0.73 | $86.19 |
Enterprise Value | -$1.21M | $20.54B |
Dividend Yield | — | 4.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.7878, up 0.88% today, but remains in a bearish technical trend. The company shows strong gross margins of 69.69% and double-digit revenue growth, but faces significant profitability challenges with negative net income margins and ROE. Recent developments include a reverse stock split, new CEO appointment, and strategic partnerships expanding pediatric care footprint.
While NUWE demonstrates operational progress with revenue growth and margin improvement, persistent losses and negative cash flow present substantial risk. The mixed analyst sentiment and bearish technical indicators suggest cautious approach. Investment appeal hinges on successful execution of financial efficiency strategy and path to profitability.
T. Rowe Price (TROW) trades at $109.42, down 0.33% on the day, with a bearish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 10.99, net income margin of 29.26%, and consistent dividend payments. Recent developments include the acquisition of F/m Investments to expand fixed-income ETF capabilities and significant AI adoption across operations. Revenue has grown from $6.5B in 2022 to $7.3B in 2025, with net income reaching $2.09B.
TROW presents a mixed outlook with attractive valuation metrics and solid profitability offset by bearish technical indicators and equity outflows. The consensus price target of $112.50 suggests modest upside potential. Key risks include market-sensitive revenue streams and competitive pressures in asset management. Institutional buying from firms like BlackRock provides support, but investors should weigh the strong fundamentals against near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
